California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts

California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts

The New York Times - Business:

The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut the initiative before any new product emerges.

Benjamin Ryan
Author: Benjamin Ryan

This post first appeared in The New York Times - Business. Read the original article.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *